EIKONIZO THERAPEUTICS, INC.

Beverly, MA · Founded 2017 · CIK 0001735756 · Biotech · Private

HDAC6-selective small molecule inhibitors to restore titin stiffness in dilated cardiomyopathy

eikonizo.com →
Grants
$1.3M
3 awards
Sector median: 1
Raised
$2.4M
2 Form D · May 2018
101 months since last filing
Contracts
—
No federal contracts on record
Patents
21
5 granted · 16 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$2,000,000
Private capital raisedForm D · SEC$371,352
Federal grantDepartment of Health and Human Services · Phase I · Targeting HDAC6 to Modulate Titin Stiffness for Dilated Cardiomyopathy Therapy$300,000
Federal grantDepartment of Health and Human Services · Phase I · Mechanistic Validation of Selective Brain-Penetrant HDAC6 Inhibitors as a Disease- Modifying Treatment for Tauopathies including Alzheimer's Disease$509,672
Federal grantDepartment of Health and Human Services · Phase I · Next-Generation CNS-Penetrant HDAC6 Inhibitors: Proof-of-Principle in Parkinson's Disease$499,766
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2535Deverra Therapeutics—$2.5M
2536ELIAS Animal Health, LLC—$2.4M
2537BIOIO, LLC——
2538EIKONIZO THERAPEUTICS, INC.—$2.4M
2539Topos Bio, Inc.—$9.0M
2540Addition Therapeutics—$28M
2541NBO Pharma Inc.—$7.6M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 4 related persons
  • Kevin KinsellaDirector
  • Janice KranzDirector · Executive Officer
  • William ShawDirector · Executive Officer
  • Stacie WeningerDirector

Patents

USPTO · 5 granted of 21

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.